Literature DB >> 16622187

Toll-like receptor 4 contributes to colitis development but not to host defense during Citrobacter rodentium infection in mice.

Mohammed A Khan1, Caixia Ma, Leigh A Knodler, Yanet Valdez, Carrie M Rosenberger, Wanyin Deng, B Brett Finlay, Bruce A Vallance.   

Abstract

Enteropathogenic Escherichia coli (EPEC) and enterohemorrhagic E. coli (EHEC) are noninvasive bacterial pathogens that infect their hosts' intestinal epithelium, causing severe diarrheal disease. These infections also cause intestinal inflammation, although the mechanisms underlying the inflammatory response, as well as its potential role in host defense, are unclear. Since these bacteria are gram-negative, Toll-like receptor 4 (TLR4), the innate receptor for bacterial lipopolysaccharide may contribute to the host response; however, the role of TLR4 in the gastrointestinal tract is poorly understood, and its impact has yet to be tested against this family of enteric bacterial pathogens. Since EPEC and EHEC are human specific, we infected mice with Citrobacter rodentium, a mouse-adapted attaching and effacing (A/E) bacterium that infects colonic epithelial cells, causing colitis and epithelial hyperplasia, using a similar array of virulence proteins as EPEC and EHEC. We demonstrated that C. rodentium activates TLR4 and rapidly induced NF-kappaB nuclear translocation in host cells in a partially TLR4-dependent manner. Infection of TLR4-deficient mice revealed that TLR4-dependent responses mediate much of the inflammation and tissue pathology seen during infection, including the induction of the chemokines MIP-2 and MCP-1, as well as the recruitment of macrophages and neutrophils into the infected intestine. Surprisingly, spread of C. rodentium through the colon was delayed in TLR4-deficient mice, whereas the duration of the infection was unaffected, indicating that TLR4-mediated responses against this A/E pathogen are not host protective and are ultimately maladaptive to the host, contributing to both the morbidity and the pathology seen during infection.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16622187      PMCID: PMC1459750          DOI: 10.1128/IAI.74.5.2522-2536.2006

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  58 in total

Review 1.  Microbes and microbial toxins: paradigms for microbial-mucosal interactions III. Shigellosis: from symptoms to molecular pathogenesis.

Authors:  P J Sansonetti
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2001-03       Impact factor: 4.052

2.  Structural studies on the O-polysaccharide of the lipopolysaccharide produced by Citrobacter rodentium (ATCC 51459).

Authors:  L L MacLean; M B Perry
Journal:  Eur J Biochem       Date:  2001-11

3.  Pretreatment of mice with streptomycin provides a Salmonella enterica serovar Typhimurium colitis model that allows analysis of both pathogen and host.

Authors:  Manja Barthel; Siegfried Hapfelmeier; Leticia Quintanilla-Martínez; Marcus Kremer; Manfred Rohde; Michael Hogardt; Klaus Pfeffer; Holger Rüssmann; Wolf-Dietrich Hardt
Journal:  Infect Immun       Date:  2003-05       Impact factor: 3.441

4.  Toll-like receptor-4 is required for intestinal response to epithelial injury and limiting bacterial translocation in a murine model of acute colitis.

Authors:  Masayuki Fukata; Kathrin S Michelsen; Rajaraman Eri; Lisa S Thomas; Bing Hu; Katie Lukasek; Cynthia C Nast; Juan Lechago; Ruliang Xu; Yoshikazu Naiki; Antoine Soliman; Moshe Arditi; Maria T Abreu
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2005-05       Impact factor: 4.052

Review 5.  Diarrheagenic Escherichia coli.

Authors:  J P Nataro; J B Kaper
Journal:  Clin Microbiol Rev       Date:  1998-01       Impact factor: 26.132

6.  Cutting edge: cell surface expression and lipopolysaccharide signaling via the toll-like receptor 4-MD-2 complex on mouse peritoneal macrophages.

Authors:  S Akashi; R Shimazu; H Ogata; Y Nagai; K Takeda; M Kimoto; K Miyake
Journal:  J Immunol       Date:  2000-04-01       Impact factor: 5.422

Review 7.  Molecular pathogenesis of Citrobacter rodentium and transmissible murine colonic hyperplasia.

Authors:  S A Luperchio; D B Schauer
Journal:  Microbes Infect       Date:  2001-04       Impact factor: 2.700

8.  Organ specificity, colonization and clearance dynamics in vivo following oral challenges with the murine pathogen Citrobacter rodentium.

Authors:  Siouxsie Wiles; Simon Clare; James Harker; Alan Huett; Douglas Young; Gordon Dougan; Gad Frankel
Journal:  Cell Microbiol       Date:  2004-10       Impact factor: 3.715

9.  The eae gene of Citrobacter freundii biotype 4280 is necessary for colonization in transmissible murine colonic hyperplasia.

Authors:  D B Schauer; S Falkow
Journal:  Infect Immun       Date:  1993-11       Impact factor: 3.441

10.  Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene.

Authors:  A Poltorak; X He; I Smirnova; M Y Liu; C Van Huffel; X Du; D Birdwell; E Alejos; M Silva; C Galanos; M Freudenberg; P Ricciardi-Castagnoli; B Layton; B Beutler
Journal:  Science       Date:  1998-12-11       Impact factor: 47.728

View more
  80 in total

1.  TRIF mobilizes unique primary defense against Gram-negative bacteria in intestinal interface.

Authors:  John Sotolongo; Saravana Kanagavelu; Jinhee Hyun; Jose Ruiz; Masayuki Fukata
Journal:  Gut Microbes       Date:  2012-06-20

2.  Dissemination of invasive Salmonella via bacterial-induced extrusion of mucosal epithelia.

Authors:  Leigh A Knodler; Bruce A Vallance; Jean Celli; Seth Winfree; Bryan Hansen; Marinieve Montero; Olivia Steele-Mortimer
Journal:  Proc Natl Acad Sci U S A       Date:  2010-09-27       Impact factor: 11.205

3.  Ecto-5'-nucleotidase and intestinal ion secretion by enteropathogenic Escherichia coli.

Authors:  John K Crane; Irina Shulgina; Tonniele M Naeher
Journal:  Purinergic Signal       Date:  2007-05-17       Impact factor: 3.765

4.  Stimulus-selective crosstalk via the NF-κB signaling system reinforces innate immune response to alleviate gut infection.

Authors:  Balaji Banoth; Budhaditya Chatterjee; Bharath Vijayaragavan; M V R Prasad; Payel Roy; Soumen Basak
Journal:  Elife       Date:  2015-04-23       Impact factor: 8.140

5.  Comparison of a classical Th1 bacteria versus a Th17 bacteria as adjuvant in the induction of experimental autoimmune encephalomyelitis.

Authors:  Alan J Smith; Yue Liu; Haiyan Peng; Rachel Beers; Michael K Racke; Amy E Lovett-Racke
Journal:  J Neuroimmunol       Date:  2011-06-28       Impact factor: 3.478

6.  Interleukin-1 receptor signaling protects mice from lethal intestinal damage caused by the attaching and effacing pathogen Citrobacter rodentium.

Authors:  Sarah L Lebeis; Kimberly R Powell; Didier Merlin; Melanie A Sherman; Daniel Kalman
Journal:  Infect Immun       Date:  2008-12-15       Impact factor: 3.441

7.  Modulation of intestinal goblet cell function during infection by an attaching and effacing bacterial pathogen.

Authors:  Kirk S B Bergstrom; Julian A Guttman; Mohammad Rumi; Caixia Ma; Saied Bouzari; Mohammed A Khan; Deanna L Gibson; A Wayne Vogl; Bruce A Vallance
Journal:  Infect Immun       Date:  2007-11-05       Impact factor: 3.441

8.  Development of fatal colitis in FVB mice infected with Citrobacter rodentium.

Authors:  Diana Borenshtein; Prashant R Nambiar; Elizabeth B Groff; James G Fox; David B Schauer
Journal:  Infect Immun       Date:  2007-04-30       Impact factor: 3.441

9.  Tumor suppressor Foxo3a is involved in the regulation of lipopolysaccharide-induced interleukin-8 in intestinal HT-29 cells.

Authors:  Lobke Snoeks; Christopher R Weber; Jerrold R Turner; Mitra Bhattacharyya; Kaarin Wasland; Suzana D Savkovic
Journal:  Infect Immun       Date:  2008-08-04       Impact factor: 3.441

Review 10.  The role of intestinal microbiota in the development and severity of chemotherapy-induced mucositis.

Authors:  Michel J van Vliet; Hermie J M Harmsen; Eveline S J M de Bont; Wim J E Tissing
Journal:  PLoS Pathog       Date:  2010-05-27       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.